Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer

Published:2019-05-09 Issue:8 Volume:8 Page:577-586
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Schneider Benjamin K.¹,Boyer Arnaud²³,Ciccolini Joseph²,Barlesi Fabrice³,Wang Kenneth⁴,Benzekry Sebastien¹⁵,Mochel Jonathan P.¹

Affiliation:

1. Iowa State University College of Veterinary Medicine Ames Iowa USA

2. SMARTc Unit Centre de Recherche en Cancérologie de Marseille Unité Mixte de Recherche (UMR) Inserm U1068 Aix Marseille University Marseille France

3. Multidisciplinary Oncology and Therapeutic Innovations Department Assistance Publique Hôpitaux de Marseille Marseille France

4. Mayo Clinic Rochester Minnesota USA

5. Team Modelisation en Oncologie Inria Bordeaux Sud‐Ouest Institut de Mathématiques de Bordeaux Talence France

Publisher

Wiley

Subject

Pharmacology (medical),Modelling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12415

Reference45 articles.

1. Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial

2. Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)

3. Pharmacology and Mechanism of Action of Pemetrexed

4. Influence of cisplatin intrastrand crosslinking on the conformation, thermal stability, and energetics of a 20-mer DNA duplex.

5. Persistence of cisplatin-induced DNA interstrand crosslinking in peripheral blood mononuclear cells from elderly and young individuals

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harnessing tumor immunity with cytotoxics: T cells monitoring in mice bearing lung tumors treated with anti-VEGF and pemetrexed-cisplatin doublet;British Journal of Cancer;2023-07-31

2. Angiogenic inhibitor pre‐administration improves the therapeutic effects of immunotherapy;Cancer Medicine;2023-02-19

3. Metronomic Anti-Cancer Therapy: A Multimodal Therapy Governed by the Tumor Microenvironment;Cancers;2021-10-28

4. Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer;JAMA Network Open;2021-07-26

5. Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer;Nature Communications;2021-06-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3